La vendita allo scoperto per Boston Scientific dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Boston Scientific. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Boston Scientific (NYSE:BSX) Azioni, Report sulle vendite allo scoperto

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States Dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally.
&nbsp;
Boston Scientific expects to complete the transaction in the first half of 2025, subject to customary closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2025 and is expected to be slightly dilutive on a GAAP basis due to amortization expense and acquisition-related net charges.

Large Cap

News

Health Care

General

Boston Scientific Has Agreed To Acquire Cortex, An Ajax Health Company, Specific Deal Terms Were Not Disclosed

Needham analyst Mike Matson reiterates Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Boston Scientific

On Wednesday,&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) released the results of the primary endpoint of the ACURATE IDE trial of&nbsp;ACURATE&nbsp;neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41629382/acurate-neo2-aortic-valve-system-data-presented-at-late-breaking-clinical-trial-session-at-tct-202" rel="noreferrer noopener">open-heart surgery</a>.
The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.
This randomized trial evaluated the ACURATE&nbsp;neo2 valve, the company&#8217;s second-generation transcatheter aortic valve replacement (TAVR) technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system.
SAPIEN valve is sold by Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and Evolut is Medtronic Plc&#8217;s NYSE: MDT) brand.
The composite rate of all-cause mortality, stroke, or rehospitalization at one year was 16.16% in the ACURATE&nbsp;neo2 arm and 9.53% in the control arm, not meeting the prespecified criterion for non-inferiority (the posterior probability for non-inferiority was 77.9%, which is lower than the non-inferiority test threshold of 97.5%).
&#8220;This trial is the largest randomized comparison of TAVR platforms and was conducted over four years, including during a global pandemic that introduced complexities for enrollment,&#8221; said&nbsp;Michael Reardon, co-principal investigator of the ACURATE IDE trial.
The company also presented data from a post-hoc analysis to identify and evaluate expanded and under-expanded ACURATE&nbsp;neo2 valve frames within the ACURATE IDE trial.
The company reviewed key procedural factors, including pre-and post-dilation, which help prepare for, enable, and confirm proper valve expansion during the procedure.
Following this review, an assessment of implant quality for the ACURATE&nbsp;neo2 valve was initiated. The assessment highlighted that approximately 20% of the valves were under-expanded.
Data from the assessment also demonstrated that the rate of death, stroke, or rehospitalization at one year was similar between the ACURATE&nbsp;neo2 expanded group and the control group.
Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S.
The ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are approved in Europe.
In the&nbsp;U.S., the ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are investigational devices.
Price Action: BSX stock is down 1.66% at $83.16 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41630458/cdw-shares-dip-as-q3-sales-miss-amid-weak-hardware-demand-and-customer-delays" target="_blank" rel="noreferrer noopener">CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays</a></li>
</ul>

Movers

Trading Ideas

Why is Boston Scientific Stock Trading Lower On Wednesday?

Biotech

Boston Scientific's ACURATE neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024

<a href="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk" title="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk">https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk</a>

Shares Of Boston Scientific See Volume; Company To Provide Cardiology Business Update At 4:00 PM EDT

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 15 years by 4.92% on an annualized basis producing an average annual return of 17.01%. Currently, Boston Scientific has a market capitalization of $125.17 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 15 years ago, it would be worth $10,630.79 today based on a price of $85.00 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730215821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $11,000 Today

Bernstein analyst Lee Hambright maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $92 to $100.

Price Target

Bernstein Maintains Outperform on Boston Scientific, Raises Price Target to $100

Morgan Stanley analyst Patrick Wood maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $92 to $100.

Morgan Stanley Maintains Overweight on Boston Scientific, Raises Price Target to $100

RBC Capital analyst Shagun Singh maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $95 to $98.

RBC Capital Maintains Outperform on Boston Scientific, Raises Price Target to $98

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Overweight and raises the price target from $87 to $98.

Wells Fargo Maintains Overweight on Boston Scientific, Raises Price Target to $98

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $92 to $98.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $98

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and maintains $98 price target.

Canaccord Genuity Maintains Buy on Boston Scientific, Maintains $98 Price Target

Mizuho analyst Anthony Petrone maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform and raises the price target from $100 to $110.

Mizuho Maintains Outperform on Boston Scientific, Raises Price Target to $110

In December 2023, Boston Scientific Corporation (NYSE:&nbsp;BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line treatment for persistent atrial fibrillation (AF).
Persistent atrial fibrillation (AFib) is&nbsp;a condition where an irregular heart rhythm lasts for more than a week.
The company <a target="_blank" href="https://news.bostonscientific.com/2023-12-28-Boston-Scientific-Initiates-AVANT-GUARD-Clinical-Trial-to-Evaluate-FARAPULSE-TM-Pulsed-Field-Ablation-System-as-First-Line-Treatment-for-Persistent-Atrial-Fibrillation" rel="noreferrer noopener">said</a> that it is the only trial to study using PFA as frontline therapy in patients with this form of AF.
Outcomes of ablation with the FARAPULSE PFA System—a nonthermal treatment in which electric fields selectively ablate heart tissue—will be compared to outcomes following the use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41490484/boston-scientific-q3-earnings-revenue-and-eps-beat-lifts-annual-forecast-on-strong-demand-for-heart" rel="noreferrer noopener">Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices</a>.
The randomized AVANT GUARD trial was expected to enroll over 500 patients.
In its third-quarter earnings investor call, Boston Scientific&#8217;s Michael Mahoney, Chairman and CEO, said, &#8220;As we have neared the end of this enrollment, we have elected to temporarily pause the trial to assess a few unanticipated observations. It is our intention to resume enrollments in the near term.&#8221;
The CEO added that due to a few unanticipated observations in the trial, which is studying an entirely new population, which is drug-naive patients with persistent AF, which FARAPULSE is not currently indicated to treat.
The company has temporarily paused enrollment until it better understands the observations. The company added that none of the observations were life-threatening.
Kenneth Stein &#8211; Senior Vice President, Global Chief Medical Officer said, &#8220;And this in no way at all affects our confidence in the overall performance of the FARAPULSE system as it&#8217;s being used today commercially or in other clinical trials.&#8221;
&#8220;I just want to emphasize that the patient population we&#8217;re studying in AVANT GUARD—which is drug-naive, persistent AF patients—has not previously been studied,&#8221; said Stein. &#8220;It is a population that&#8217;s not indicated for ablation today under guidelines, and it&#8217;s not the population that&#8217;s being treated today with the Farapulse system.&#8221;
Price Action: BSX stock is down 1.52% at $86.67 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41497142/neuropsychiatry-focused-alto-neurosciences-mid-stage-depression-trial-disappoints-analyst-notes-f" target="_blank" rel="noreferrer noopener">Neuropsychiatry-Focused Alto Neuroscience&#8217;s Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform</a>.</li>
</ul>
Photo via Shutterstock

Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm

Wall Street is on track for its third consecutive day of losses as investors grow cautious about risky assets, awaiting more clarity on U.S. fiscal and monetary policies and scrutinizing the latest <a href="https://www.benzinga.com/earnings">batch of corporate earnings.</a>
Both equities and commodities took a hit on Wednesday, while the U.S. dollar gained strength, attracting investor flows as traders moved to safer cash positions.
The U.S. dollar index, as tracked by the the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose 0.5%, reaching levels last seen in late July. 
At midday in New York, the S&amp;P 500 was down 0.7%, attempting to hold support around the 5,800-point level. The Dow Jones also dropped 0.7%, and tech stocks, along with small caps, fared worse, sliding by 0.9%.
On the data front, mortgage applications declined for the fourth straight week, reflecting continued pressure <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41488744/mortgage-applications-fall-for-fourth-straight-week-as-high-rates-squeeze-homebuy">from elevated borrowing costs.</a>
Existing home sales fell by 1% in September to a seasonally adjusted annualized rate of 3.84 million, the lowest level since October 2010. This follows an upwardly revised 3.88 million in August and missed forecasts of 3.9 million.
Despite weak housing data, real estate stocks showed surprising resilience. The Vanguard Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNQ#NYSE">VNQ</a>) and the SPDR Homebuilders ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHB#NYSE">XHB</a>) moved higher after two straight sessions of losses.
Gold prices, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), fell more than 1%, pulling mining stocks down with it. Silver plummeted over 3%, retreating from 12-year highs reached on Tuesday.
Oil prices slipped by 1%, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) tumbled 2%. 
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,815.02</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,625.59</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,196.24</td>
<td>-0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated 12:00 p.m. ET </figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.6% to $579.72.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.7% lower to $426.41.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 1% to $491.16.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% $219.80.</li>
<li>The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 0.6%. The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 2.4% after reporting a worse-than-expected losses<a href="https://www.benzinga.com/news/earnings/24/10/41486950/boeing-q3-earnings-revenue-and-profit-decline-cultural-challenges-ceo-ortberg-vows-transformation"> last quarter</a>.</li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), up 3.5%.</li>
<li>Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), up 3.9%.</li>
<li>Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), down over 7%.</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>), up over 6%.</li>
<li>Manhattan Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>), down over 7%.</li>
<li>East West Bancorp. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>), up over 7%.</li>
<li>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), down over 13%.</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), down 2.2%. </li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), down 2.9%.</li>
<li>NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), down 0.1%. </li>
<li>AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), up 3.8%. </li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), down 3.7%. </li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>), down 0.9%. </li>
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), down 1.6%. </li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>), down 2.6%. </li>
<li>Vertiv Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), down 2.8%. </li>
<li>Old Dominion Freight Line Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>), down 4.8%. </li>
</ul>
Large-cap companies reporting earnings after the close include Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>). 
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/bonds/24/10/41455678/gold-on-track-for-best-year-since-1979-veteran-investor-says-sell-bonds-buy-gold">Gold On Track For Best Year Since 1979: Veteran Investor Says &#8216;Sell Bonds, Buy Gold&#8217;</a></li>
</ul>

Equities

Macro Economic Events

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

EWBC

LRCX

MANH

ODFL

TMUS

TSLA

PowerShares DB US Dollar Index Bullish Fund

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?

WIIM

Boston Scientific shares are trading lower after the company temporarily paused the AVANT GUARD trial to assess unanticipated observations.

Whales with a lot of money to spend have taken a noticeably bullish stance on Boston Scientific.
Looking at options history for Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $1,054,466 and 4, calls, for a total amount of $374,985.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $78.0 and $90.0 for Boston Scientific, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Boston Scientific's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Boston Scientific's substantial trades, within a strike price spectrum from $78.0 to $90.0 over the preceding 30 days.
<h3>Boston Scientific Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729694740_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$6.6</td>
<td>$6.4</td>
<td>$6.4</td>
<td>$90.00</td>
<td>$320.0K</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.6</td>
<td>$90.00</td>
<td>$211.1K</td>
<td>1.0K</td>
<td>392</td>
</tr>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.5</td>
<td>$0.4</td>
<td>$0.4</td>
<td>$78.00</td>
<td>$194.2K</td>
<td>1</td>
<td>1.4K</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.6</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$84.00</td>
<td>$148.0K</td>
<td>0</td>
<td>627</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.45</td>
<td>$2.35</td>
<td>$2.4</td>
<td>$84.00</td>
<td>$83.5K</td>
<td>0</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Boston Scientific</h3>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
In light of the recent options history for Boston Scientific, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Boston Scientific Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 5,478,627, the BSX's price is down by -4.41%, now at $84.13. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>What Analysts Are Saying About Boston Scientific</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $96.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Boston Scientific, targeting a price of $90. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Boston Scientific with a target price of $98. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Boston Scientific, maintaining a target price of $95. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Boston Scientific, targeting a price of $100. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Boston Scientific with a target price of $100. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Boston Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Behind the Scenes of Boston Scientific's Latest Options Trends

On Wednesday, Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) reported third-quarter revenues of $4.21 billion, beating the&nbsp;consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of $4.04 billion</a>.
Sales increased 19.4% on a reported basis, compared to the company's guidance range of 13%-15%, and 19.5% on an operational basis, 18.2% on an organic basis, compared to the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39938250/boston-scientific-q2-earnings-strong-performance-of-cardiovascular-devices-leads-to-2024-guidance-h" rel="noreferrer noopener">guidance range of 13%-15%</a>.
The company earned an adjusted EPS of $0.63, beating the consensus of $0.59 and the management&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41483072/boston-scientific-announces-results-for-third-quarter-2024" rel="noreferrer noopener">guidance of $0.57-$0.59</a>.
The company's cardiovascular segment generated sales of $2.73 billion, rising 25% (25.1% operationally and 24.6% organically).
Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions.
MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7% organically).
Neuromodulation led the way with a 17% increase. Urology (10.3%) and Endoscopy (7.8%) followed.
Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported basis and 15% on an organic basis, compared to prior guidance of 13.5%-14.5% and 13%-14%, respectively.
Boston Scientific estimates 2024 adjusted EPS of $2.45-$2.47, compared to prior guidance of $2.38-$2.42 and the consensus of $2.41.
For the fourth quarter, the company estimates net sales growth of approximately 16.5%-18.5% on a reported basis and 14%-16% on an organic basis.
The company forecasts adjusted EPS of $0.64-$0.66 versus consensus of $0.64.
<h2 class="wp-block-heading">Boston Scientific Stock Prediction For 2024</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Boston Scientific have an average 1-year price target of $91.47, representing an expected upside of 7.71%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Boston Scientific, while 17 analysts have bullish ratings. The street high price target from B of A Securities is $100.0, while the street low from Deutsche Bank is $78.0.
Price Action: BSX stock is down 5.31% at $83.34 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41484529/hilton-worldwide-q3-earnings-beats-estimates-on-higher-occupancy-stock-dips-on-lackluster-outlook" target="_blank" rel="noreferrer noopener">Hilton Worldwide Q3 Earnings Beats Estimates On Higher Occupancy, Stock Dips On Lackluster Outlook</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices

The company estimates net sales growth for the fourth quarter of 2024, versus the prior year period, to be in a range of approximately 16.5 to 18.5 percent on a reported basis, and 14 to 16 percent on an organic basis. Fourth quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.41 to $0.43 and adjusted EPS, excluding certain charges (credits), of $0.64 to $0.66.

Boston Scientific Forecasts Q4 2024 Adjusted EPS Of $0.64-$0.66 Versus Consensus Of $0.64

In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific (BSX – Research Report). The company's shares...

Boston Scientific (BSX) Gets a Hold from Needham

Bearish flow noted in Boston Scientific (BSX) with 8,976 puts trading, or 2.0x expected. Most active are 11/1 weekly 80 puts and 11/1 weekly 83 put...

Boston Scientific put volume heavy and directionally bearish

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price...

Boston Scientific (BSX) Gets a Buy from Wells Fargo

Why The Fundamentals Make Me Bullish On Boston Scientific

Business Update

Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript

Boston Scientific to acquire AFib ablation tech firm Cortex

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovani...

Boston Scientific's Strategic Acquisition of Cortex: A Boost for Long-Term Growth

Axonics' Market Growth Strengthens Boston Scientific's Future

Boston Scientific ( ($BSX) ) just unveiled an announcement. Boston Scientific Corporation has announced the resumption of its AVANT GUARD clinical ...

Boston Scientific Resumes AVANT GUARD Clinical Trial

AXNX

Press Releases

A New Standard in Drug Testing: Intelligent Bio (NASDAQ: INBS) Delivering Cost-Efficiency, Rapid Results, and Employee Dignity more stocks inside…

Boston Scientific Receives FDA Approval for Expanded Indication of INGEVITY™+ Pacing Leads to Include Conduction System Pacing of the Left Bundle Branch Area

Comments

Boston Scientific

Vendite allo scoperto

Boston Scientific (NYSE:BSX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO